Semasize/ Obesema / Hepaglide
by Alkem Laboratories · DCGI approved March 2026
| Active ingredient | Semaglutide (GLP-1 receptor agonist) |
| Indication | Type 2 Diabetes + Obesity |
| Manufacturer | Alkem Laboratories Ltd |
| DCGI status | Approved March 2026 |
| Price (MRP) | ₹1,800–3,500/month Lowest-priced prefilled pen semaglutide in India — ₹1,800/month for the T2D starting dose |
| Format | Prefilled pen |
| Prescription | Schedule H — required |
How Semasize compares
Semasize is Alkem's prefilled-pen semaglutide and the lowest-priced pen format on the Indian market — making patient self-administration affordable in a way the cheaper vial-only options (SUNDAE) cannot. Obesema and Hepaglide are Alkem's sister brand names for distinct prescribing channels.
About Alkem Laboratories
Alkem Laboratories is one of India's top-five pharmaceutical companies by domestic sales, with strong franchise positions in anti-infectives and metabolic health. The Semasize pricing strategy — undercutting the Zydus reusable-pen pricing while keeping a familiar disposable-pen format — targets prescribers and patients who prioritise simplicity.
Manufacturer announcement
Additional source
Outlook Business — Alkem semaglutide pricingGLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.